Abstract
Epithelial ovarian cancer (EOC) is a highly lethal gynaecological malignancy. Cisplatin is the basal chemotherapeutic agent used to treat EOC, but resistance to cisplatin leads to chemotherapy failure. MicroRNAs are a novel class of regulators that function by controlling gene expression at the post-transcriptional level. Several recent reports have identified some microRNAs that are related to chemotherapy sensitivity. In this study, we found two microRNAs miR-152 and miR-185 that were significantly downregulated in the cisplatin-resistant ovarian cell lines SKOV3/DDP and A2780/DDP, compared with their sensitive parent line SKOV3 and A2780, respectively. Subsequently, the roles of miR-152 and miR-185 were evaluated in vitro and in vivo. The overexpression of miR-152 or miR-185 increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis, then we further confirmed that these miRNAs functioned through suppressing DNA methyltransferase 1 (DNMT1) directly. Concordantly, CD-1/CD-1 nude mice that were injected intraperitoneally with SKOV3/DDP cells transfected with miR-152 mimics exhibited upregulated cisplatin sensitivity in vivo. Interestingly, we found that there were no significant changes in the expression of these two microRNAs after treatment with decitabine (DAC), a traditional epigenetic therapeutic agent, suggesting these miRNAs represented two new regulators independent of DAC. Finally, the survival assay in A549 and HepG2 cells revealed that the two microRNAs involved in cisplatin sensitivity were related to cell types. Our results indicated that miR-152 and miR-185 were involved in ovarian cancer cisplatin resistance in vitro and in vivo by targeting DNMT1 directly. These molecules may serve as potential epigenetic therapeutic targets in other cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Singh RK, Lange TS, Kim KK, Shaw SK, Brard L . A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells. Gynecol Oncol 2008; 109: 240–249.
Cho KR, Shih Ie M . Ovarian cancer. Annu Rev Pathol 2009; 4: 287–313.
Ozols RF, Young RC . Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 222–232.
Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC . Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001; 61: 1291–1295.
Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P . Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195–208.
Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009; 2: 34.
Lenzi R, Frost P, Abbruzzese JL . Modulation of cisplatin resistance by 2′-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 1994; 14: 247–251.
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R . Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039–6044.
Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010; 116: 4043–4053.
Tohyama K . Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes. Curr Pharm Des 2012; 18: 3190–3197.
Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 119: 6025–6031.
Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K . Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 2012; 188: 4441–4449.
Yi TZ, Li J, Han X, Guo J, Qu Q, Guo L et al. DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy 2012; 58: 19–29.
Luszczek W, Cheriyath V, Mekhail TM, Borden EC . Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther 2010; 9: 2309–2321.
Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72: 2197–2205.
Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010; 150: 189–195.
Kantarjian HM, Issa JP . Decitabine dosing schedules. Semin Hematol 2005; 42: S17–S22.
Malizia AP, Wang DZ . MicroRNAs in cardiomyocyte development. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 183–190.
Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011; 30: 4386–4398.
Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079–31086.
Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152–2159.
Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425–433.
Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008; 68: 10307–10314.
Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep 2012; 27: 447–454.
Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71: 6450–6462.
Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer 2011; 10: 124.
Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, Ferrell JE et al. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 2009; 7: e1000238.
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 2011; 129: 2600–2610.
Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G . Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009; 379: 726–731.
Barabas K, Milner R, Lurie D, Adin C . Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008; 6: 1–18.
Basu A, Krishnamurthy S . Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids 2010; 2010.
Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573–584.
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA . DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193–204.
Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC . Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311–1316.
Ishida S, Lee J, Thiele DJ, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298–14302.
Kwon MJ, Shin YK . Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci 2011; 12: 983–1008.
Jones PA, Baylin SB . The epigenomics of cancer. Cell 2007; 128: 683–692.
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008; 5: e114.
Tang M, Xu W, Wang Q, Xiao W, Xu R . Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics 2009; 10: 336–352.
Fan H, Zhao ZJ, Cheng J, Su XW, Wu QX, Shan YF . Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J Gastroenterol 2009; 15: 2020–2026.
Qin T, Jelinek J, Si J, Shu J, Issa JP . Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659–667.
Matei DE, Nephew KP . Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol 2010; 116: 195–201.
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010; 14: 1170–1179.
Huang J, Wang Y, Guo Y, Sun S . Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52: 60–70.
Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata DM, Xie H et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 2011; 39: 311–318.
Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010; 29: 4971–4979.
Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71: 225–233.
Zhang J, Han C, Wu T . MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 2012; 143: e248.
Fu X, Tian J, Zhang L, Chen Y, Hao Q . Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012; 586: 1279–1286.
Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F et al. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J 2012; 444: 291–301.
Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 2012; 122: 2637–2651.
Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010; 70: 367–377.
Liao JM, Lu H . Autoregulatory suppression of c-Myc by miR-185-3p. J Biol Chem 2011; 286: 33901–33909.
Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J . MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009; 4: e6677.
Glasspool RM, Teodoridis JM, Brown R . Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94: 1087–1092.
Chen H, Hardy TM, Tollefsbol TO . Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2011; 2: 67.
Acknowledgements
This work was supported by the Natural Science Foundation of Heilongjiang Province for youth (QC2010002) and for outstanding youth (JC201110), the Natural Science Foundation of China (81101373/81270511/81001033), the Science Foundation of Health Department of Heilongjiang Province(2012-525) and the Science Foundation of the First Affiliated Hospital of Harbin Medical University (2009Y24).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Xiang, Y., Ma, N., Wang, D. et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33, 378–386 (2014). https://doi.org/10.1038/onc.2012.575
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.575
Keywords
This article is cited by
-
Metformin regulates expression of DNA methyltransferases through the miR-148/-152 family in non-small lung cancer cells
Clinical Epigenetics (2023)
-
The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer
Scientific Reports (2023)
-
MiR-29a-3p inhibits high-grade transformation and epithelial–mesenchymal transition of lacrimal gland adenoid cystic carcinoma by targeting Quaking
Molecular Biology Reports (2023)
-
linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer
Reproductive Biology and Endocrinology (2022)
-
RETRACTED ARTICLE: SOX2 Regulates lncRNA CCAT1/MicroRNA-185-3p/FOXP3 Axis to Affect the Proliferation and Self-Renewal of Cervical Cancer Stem Cells
Nanoscale Research Letters (2021)